Intravenous Immunoglobulin G (IVIG) Need Assessment Survey Toward Local Manufacturing of IVIG Using a Mini-Pool Plasma Fractionation Technique

Immunoglobulin therapy has a crucial role in the treatment of primary and secondary immunodeficiencies as well as in a multitude of neurologic, hematologic, infectious, and autoimmune conditions. In the current study, a preliminary pilot scale needs assessment survey was conducted to examine the need for IVIG among patients in Addis Ababa, Ethiopia, and in so doing justify local manufacturing of IVIG products. The survey was performed by administering a structured questionnaire to private and government hospitals, a national blood bank, a regulatory body, and healthcare researchers working in academia and pharmaceutical companies. The questionnaire encompassed demographics and specific IVIG-related questions designed for each institution. Responses supplied in the study provide qualitative data. Our findings indicated that IVIG has been registered by the regulatory body for use in Ethiopia and there is a demand for the product in the country. The study also highlights that patients go as far as to clandestine markets to procure IVIG products at a cheaper price. To impede such illegal routes and make the product readily accessible, a small-scale and low-cost approach such as a mini-pool plasma fractionation technique could be implemented to locally purify and prepare IVIG using plasma collected through the national blood donation program.

[1]  G. Curigliano,et al.  The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. , 2021, Journal of cancer policy.

[2]  W. Kamitani,et al.  Neutralizing and binding activities against SARS‐CoV‐1/2, MERS‐CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan , 2020, Transfusion.

[3]  Nicole M. Bouvier,et al.  Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study , 2020, Nature Medicine.

[4]  G. Vidarsson,et al.  The Ligands for Human IgG and Their Effector Functions , 2019, Antibodies.

[5]  C. Barrios,et al.  Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab , 2019, Ecancermedicalscience.

[6]  A. Binagwaho,et al.  Affordability of Cancer Drugs in Sub-Saharan Africa: Effects of Pricing on Needless Loss of Life. , 2017, JAMA oncology.

[7]  S. Miescher,et al.  Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection , 2017, EBioMedicine.

[8]  Peter G. Smith,et al.  The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Burnouf,et al.  Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries , 2015, PLoS neglected tropical diseases.

[10]  J. Goudemand,et al.  Solvent‐detergent filtered (S/D‐F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system , 2010, Transfusion medicine.

[11]  Y. Shoenfeld,et al.  Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature , 2009, Clinical reviews in allergy & immunology.

[12]  H. Goubran,et al.  New methods of plasma fractionation – a presentation of the ‘mini‐pool’ fractionation procedure developed in Egypt , 2009 .

[13]  F. Bonilla Intravenous immunoglobulin: adverse reactions and management. , 2008, The Journal of allergy and clinical immunology.

[14]  J. Goudemand,et al.  Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  S. Hoffman,et al.  Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? , 2006, Annals of Internal Medicine.

[16]  W. Sewell,et al.  Clinical uses of intravenous immunoglobulin , 2005, Clinical and experimental immunology.